Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants

Congenital cytomegalovirus is an illness that can be transmitted from the mother to baby during pregnancy. This illness can lead to multiple adverse outcomes, including impaired hearing and delayed language. This randomized controlled clinical trial in infants identified from 1 to 6 months of age with hearing impairment consequent to congenital CMV will compare hearing and language development outcomes of infants who receive 6 months of valganciclovir treatment and infants who receive placebo. Safety outcomes and side effects will also be compared between the valganciclovir treatment and control groups.

- **Aim 1**: To determine if treatment of CMV-infected hearing impaired infants with isolated hearing loss with the antiviral drug valganciclovir improves the change in best-ear hearing after 8 months compared to untreated CMV-infected hearing impaired infants

- **Aim 2**: To determine if valganciclovir treatment improves the following objectives when compared to the control group.